eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

3/2013
vol. 38
 
Share:
Share:
more
 
 
abstract:

Rapid push: new opportunities in subcutaneous immunoglobulin replacement therapy

Małgorzata Pac
,
Ewa Bernatowska

(Centr Eur J Immunol 2013; 38 (3): 388-392)
Online publish date: 2013/10/28
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Primary antibody deficiencies (PAD) are the largest group of primary immunodeficiency diseases (PID), affecting patients at various age. Affected individuals are extremely prone to serious and recurrent infections, which can led to tissue damage and premature death. Many patients require regular, life-long prophylactic treatment with immunoglobulin. For years the leading route has been intravenous infusion of immunoglobulin (IVIG). Despite its clinical benefits, IVIG is associated with some inconveniences such as travelling to hospital, difficulties obtaining vein access and systemic side effects. The alternative method to IVIG is subcutaneous immunoglobulin infusion (SCIG), introduced in the 1990s. It has become increasingly popular in recent years. This route does not require venous access, has a really low risk of systemic side effects and improves quality of life. SCIG can be administered either via programmable pump or rapid push infusion. Despite similar effectiveness and risk of adverse events the rapid push route seems to be safe and viable, providing more self-control, treatment flexibility, independence and opportunities for treatment satisfaction. Rapid push immunoglobulin infusion has recently become more popular in the USA and Canada. This route should be considered as an alternative possibility of replacement immunoglobulin therapy in patients with immunodeficiency in Europe.
keywords:

primary antibody deficiency, rapid push, subcutaneous immunoglobulin therapy, infusion pump

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe